Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 23%
Hold 41%
Sell 5%
Strong Sell 0%

Bulls say

Biogen is an established biopharmaceutical company that is making strategic moves to strengthen and diversify its portfolio, with recent acquisitions and ongoing development of potential treatments for rare diseases and neurodegenerative conditions. The company's strong financial discipline and success in the neuroscience field, along with potential commercial success of new therapies, make it a promising investment opportunity for those with a positive outlook on the stock.

Bears say

Biogen is facing significant challenges with its declining multiple sclerosis franchise and the recent setback for its Alzheimer's drug, lecanemab. Even with potential contributions from newer franchises, such as Spinraza and Skyclarys, Biogen's success may be limited due to increasing competition and uncertainty around product approvals. The company's financials may also be impacted by the CVR structure and potential generic competition for Tecfidera. Overall, Biogen may struggle to maintain its current revenue levels and profitability, leading to a negative outlook on the stock.

Biogen (BIIB) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 23% recommend Buy, 41% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 22 analysts, Biogen (BIIB) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $206.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $206.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.